Syngene International, an integrated research, development and manufacturing services company, has extended its ongoing research collaboration with Bristol Myers Squibb through the end of 2030, and will expand the breadth of drug discovery research conducted, including chemistry, biology, drug metabolism and pharmacokinetics, as well as translational medicine research and pharmaceutical development.   The extension will include a 40% increase in the number of scientists and the addition of a n...